Fresenius Income Tax Expense vs Cost Of Revenue Analysis
FMS Stock | USD 20.10 0.11 0.54% |
Fresenius Medical financial indicator trend analysis is much more than just examining Fresenius Medical Care latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fresenius Medical Care is a good investment. Please check the relationship between Fresenius Medical Income Tax Expense and its Cost Of Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Income Tax Expense vs Cost Of Revenue
Income Tax Expense vs Cost Of Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fresenius Medical Care Income Tax Expense account and Cost Of Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Fresenius Medical's Income Tax Expense and Cost Of Revenue is 0.45. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Fresenius Medical Care, assuming nothing else is changed. The correlation between historical values of Fresenius Medical's Income Tax Expense and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Fresenius Medical Care are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Income Tax Expense i.e., Fresenius Medical's Income Tax Expense and Cost Of Revenue go up and down completely randomly.
Correlation Coefficient | 0.45 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Income Tax Expense
Cost Of Revenue
Cost of Revenue is found on Fresenius Medical Care income statement and represents the costs associated with goods and services Fresenius Medical provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most indicators from Fresenius Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fresenius Medical Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Fresenius Medical's Tax Provision is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 6.94 in 2024, whereas Selling General Administrative is likely to drop slightly above 3 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.1B | 5.3B | 4.9B | 3.7B | Total Revenue | 17.6B | 19.4B | 19.5B | 11.4B |
Fresenius Medical fundamental ratios Correlations
Click cells to compare fundamentals
Fresenius Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fresenius Medical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 302.7M | 294.3M | 293.1M | 293.2M | 293.4M | 405.8M | |
Total Assets | 32.9B | 31.7B | 34.4B | 35.8B | 33.9B | 18.7B | |
Short Long Term Debt Total | 13.8B | 12.4B | 13.3B | 13.2B | 12.1B | 6.2B | |
Other Current Liab | 2.7B | 3.0B | 3.3B | 3.4B | 3.6B | 3.8B | |
Total Current Liabilities | 7.0B | 6.2B | 7.3B | 6.5B | 6.1B | 3.6B | |
Total Stockholder Equity | 13.2B | 12.3B | 14.0B | 15.4B | 13.6B | 7.8B | |
Property Plant And Equipment Net | 8.5B | 4.1B | 4.3B | 4.2B | 7.5B | 7.8B | |
Net Debt | 12.8B | 11.3B | 11.8B | 11.9B | 10.6B | 5.7B | |
Retained Earnings | 9.5B | 10.3B | 10.8B | 10.7B | 10.9B | 11.5B | |
Accounts Payable | 835.2M | 827.4M | 857.5M | 931.3M | 885.1M | 550.9M | |
Cash | 1.0B | 1.1B | 1.5B | 1.3B | 1.4B | 1.5B | |
Non Current Assets Total | 25.8B | 24.4B | 26.4B | 27.6B | 25.2B | 13.8B | |
Non Currrent Assets Other | 752.5M | 4.8B | 5.2B | 5.0B | 223.6M | 212.4M | |
Cash And Short Term Investments | 1.1B | 1.2B | 1.6B | 1.4B | 1.5B | 1.6B | |
Net Receivables | 4.0B | 3.6B | 3.9B | 4.0B | 4.1B | 2.6B | |
Common Stock Total Equity | 308.1M | 307.9M | 304.4M | 292.9M | 336.8M | 304.7M | |
Liabilities And Stockholders Equity | 32.9B | 31.7B | 34.4B | 35.8B | 33.9B | 18.7B | |
Non Current Liabilities Total | 12.7B | 13.2B | 13.1B | 13.8B | 13.0B | 7.2B | |
Inventory | 1.7B | 1.9B | 2.0B | 2.3B | 2.2B | 2.3B | |
Other Current Assets | 320.7M | 455.7M | 342.9M | 351.1M | 332.6M | 348.1M | |
Other Stockholder Equity | 4.5B | 4.0B | 4.2B | 4.8B | 3.4B | 3.2B | |
Total Liab | 19.7B | 19.4B | 20.4B | 20.3B | 19.1B | 10.8B | |
Property Plant And Equipment Gross | 8.5B | 8.2B | 4.3B | 4.2B | 17.9B | 17.0B | |
Total Current Assets | 7.2B | 7.3B | 8.0B | 8.2B | 8.7B | 4.9B | |
Accumulated Other Comprehensive Income | (1.0B) | (2.2B) | (1.3B) | (388.5M) | (975.2M) | (926.4M) | |
Short Term Debt | 3.3B | 1.7B | 2.6B | 2.0B | 1.6B | 1.1B | |
Intangible Assets | 1.4B | 1.4B | 1.5B | 1.5B | 1.4B | 1.7B | |
Common Stock | 304.4M | 292.9M | 293.0M | 293.4M | 337.4M | 258.6M | |
Current Deferred Revenue | 201.0M | 606.3M | 518.0M | 105.7M | 85.8M | 81.5M | |
Other Liab | 2.1B | 2.5B | 2.4B | 2.7B | 3.1B | 3.2B | |
Other Assets | 1.1B | 1.1B | 1.2B | 1.1B | 1.3B | 1.4B | |
Long Term Debt | 6.5B | 6.8B | 6.6B | 7.2B | 7.0B | 5.7B | |
Property Plant Equipment | 8.5B | 8.2B | 8.6B | 8.3B | 9.6B | 10.1B | |
Good Will | 14.0B | 13.0B | 14.4B | 15.8B | 14.7B | 13.9B | |
Short Term Investments | 133.3M | 161.7M | 136.4M | 170.0M | 136.3M | 140.2M | |
Net Tangible Assets | (3.5B) | (3.1B) | (3.1B) | (3.3B) | (3.8B) | (4.0B) | |
Long Term Investments | 696.9M | 761.1M | 786.9M | 773.7M | 1.3B | 853.1M | |
Short Long Term Debt | 2.6B | 1.1B | 1.9B | 1.4B | 944.6M | 1.7B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Fresenius Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Fresenius Medical's short interest history, or implied volatility extrapolated from Fresenius Medical options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Fresenius Stock analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Fresenius Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fresenius Medical. If investors know Fresenius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fresenius Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.353 | Dividend Share 1.19 | Earnings Share 0.91 | Revenue Per Share 33.1505 | Quarterly Revenue Growth (0) |
The market value of Fresenius Medical Care is measured differently than its book value, which is the value of Fresenius that is recorded on the company's balance sheet. Investors also form their own opinion of Fresenius Medical's value that differs from its market value or its book value, called intrinsic value, which is Fresenius Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fresenius Medical's market value can be influenced by many factors that don't directly affect Fresenius Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fresenius Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fresenius Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fresenius Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.